Robeco Institutional Asset Management B.V. boosted its stake in shares of Mylan NV (NASDAQ:MYL) by 63.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 262,758 shares of the company’s stock after purchasing an additional 101,541 shares during the period. Robeco Institutional Asset Management B.V. owned 0.05% of Mylan worth $7,446,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of MYL. Pinnacle Bank increased its stake in shares of Mylan by 66.4% during the first quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock worth $30,000 after purchasing an additional 423 shares during the period. Mascoma Wealth Management LLC bought a new position in shares of Mylan during the first quarter worth approximately $47,000. Kinneret Advisory LLC bought a new position in shares of Mylan during the fourth quarter worth approximately $71,000. First Hawaiian Bank increased its stake in shares of Mylan by 560.4% during the fourth quarter. First Hawaiian Bank now owns 2,886 shares of the company’s stock worth $79,000 after purchasing an additional 2,449 shares during the period. Finally, NuWave Investment Management LLC increased its stake in shares of Mylan by 18.1% during the fourth quarter. NuWave Investment Management LLC now owns 3,136 shares of the company’s stock worth $86,000 after purchasing an additional 480 shares during the period. 83.69% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have weighed in on the company. Royal Bank of Canada reduced their target price on Mylan to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, May 8th. Raymond James set a $31.00 target price on Mylan and gave the company a “buy” rating in a report on Wednesday, May 8th. Mizuho reaffirmed a “hold” rating on shares of Mylan in a report on Tuesday. Morgan Stanley set a $32.00 price objective on Mylan and gave the company a “buy” rating in a report on Wednesday, May 8th. Finally, BMO Capital Markets set a $36.00 price objective on Mylan and gave the company a “buy” rating in a report on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $37.35.
Shares of MYL stock opened at $20.41 on Thursday. The firm has a market cap of $10.35 billion, a price-to-earnings ratio of 4.46, a price-to-earnings-growth ratio of 1.04 and a beta of 1.44. Mylan NV has a 1 year low of $19.40 and a 1 year high of $42.50. The company has a current ratio of 1.51, a quick ratio of 0.85 and a debt-to-equity ratio of 1.20.
Mylan (NASDAQ:MYL) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.03. The firm had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.70 billion. Mylan had a net margin of 2.14% and a return on equity of 18.96%. The business’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.96 earnings per share. As a group, sell-side analysts expect that Mylan NV will post 4.28 EPS for the current fiscal year.
In other news, insider Paul Campbell sold 11,533 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $27.50, for a total value of $317,157.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.81% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2019/05/16/robeco-institutional-asset-management-b-v-buys-101541-shares-of-mylan-nv-myl.html.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
See Also: What is Green Investing?
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.